Immunovaccine Reports Positive Results from Two Anthrax Studies

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced positive results from anthrax
challenge studies in rabbits and non-human primates using its DepoVaX (TM)
delivery system. The studies showed that all animals administered a vaccine
containing recombinant protective antigen (PA) formulated in DepoVax were
protected against a lethal anthrax challenge. 


Importantly, a single dose of DepoVax containing five micrograms of recombinant
PA protected rabbits exposed to a lethal anthrax dose. Antibody titers plateaued
in rabbits within 28 days highlighting the DepoVax platform's potential to
enable a single-dose, rapid response anthrax vaccine. These studies, conducted
under the National Institute of Allergy and Infectious Diseases' (NIAID's)
preclinical services program, were intended to evaluate Immunovaccine's DepoVax
adjuvanting technology and advance the development of next generation
bio-defense vaccines. 


"These positive study results demonstrate the continued advancement of our
promising bio-defense vaccine development program and highlight the versatile
nature of our DepoVax platform beyond our lead clinical stage cancer vaccines,"
stated Dr. Marc Mansour, chief operating officer of Immunovaccine. "This range
of activity and development milestones underscores the potential of the DepoVax
technology to enable next generation vaccines to address a variety of
healthcare's most pressing needs."


Earlier investigation of Immunovaccine's DepoVax-formulated vaccines conducted
under the NIAID's preclinical services program had revealed their ability to
produce significant toxin neutralizing antibodies. These follow-up studies
examined whether a single vaccination in rabbits or two vaccinations in both
rabbits and non-human primates could provide sufficient immunogenicity and
protection from anthrax. 


In rabbits, NIAID-funded contractors demonstrated that a single vaccination
protected against an aerosol anthrax challenge. In non-human primates, two doses
containing recombinant PA formulated in DepoVax triggered sustained toxin
neutralizing antibodies sufficient to protect them from a lethal anthrax
challenge. A single dose response was not evaluated in non-human primates. 


The rabbit studies also showed that the DepoVax-formulated vaccines began
producing detectable and potentially protective toxin neutralizing antibodies in
as little as 14 days with maximum protective antibody levels achieved within 28
days following a single vaccination. The titers were sustained for at least 70
days at which time the lethal anthrax challenge was performed. Neutralizing
antibodies rose further in animals receiving a second dose of the DepoVax
recombinant PA vaccine. 


Preliminary data suggest that the DepoVax platform may generate a stronger
immune response than BioThrax (R), the only FDA-licensed vaccine available for
pre-exposure protection against anthrax infection.


"We are greatly encouraged that the results from these challenge studies provide
evidence that the DepoVax platform has the potential to make a single dose rapid
response anthrax vaccine a reality," said Dr. Mansour. "There is a significant
need both in the U.S. and globally for a single dose anthrax vaccine that can
provide strong protection in the shortest period of time in the event of a
bioterrorism incident."


The company plans further studies on the use of DepoVax-based recombinant PA
vaccines. 


About DepoVax (TM)

DepoVax (TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax (TM) platform possesses impressive flexibility,
allowing it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax (TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax (TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Operating Officer
(902) 492-1819
mmansour@imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com
(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024